23andMe Holding Co. (OQ:ME)

Business Focus: Medical & Diagnostic Laboratories

Feb 22, 2024 12:10 pm ET
23andMe Holding Co (NASDAQ: ME) Jewish and Chinese Users
NEW YORK, NY / ACCESSWIRE / February 22, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Feb 21, 2024 12:15 pm ET
23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
Feb 20, 2024 12:15 pm ET
23andMe Holding Co (NASDAQ:ME) Jewish and Chinese Users
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
Feb 16, 2024 12:15 pm ET
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
Feb 15, 2024 12:15 pm ET
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
Feb 14, 2024 12:15 pm ET
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
Feb 13, 2024 12:15 pm ET
23andMe Holding Co (NASDAQ: ME) Jewish and Chinese Users
NEW YORK, NY / ACCESSWIRE / February 13, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Feb 12, 2024 12:10 pm ET
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
Feb 09, 2024 12:15 pm ET
DATA BREACH- 23andMe Jewish & Chinese Consumers May be Affected
NEW YORK, NY / ACCESSWIRE / February 9, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Feb 07, 2024 04:01 pm ET
23andMe Reports Third Quarter Fiscal 2024 Financial Results
23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023. Key Results Reported total revenue of $44.7...
Jan 31, 2024 07:30 am ET
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application for 23ME-01473 (‘1473), a natural killer...
Jan 30, 2024 10:12 pm ET
23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, announced a month-long initiative to amplify Ava DuVernay’s new film ORIGIN and the film’s groundbreaking Seat16 program. Seat16 allows anyone to...
Jan 24, 2024 04:05 pm ET
23andMe to Report FY2024 Third Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the...
Dec 19, 2023 08:00 am ET
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced the further expansion of the ongoing 23ME-00610 Phase 1/2a study to include an additional 30 patients with advanced neuroendocrine and...
Dec 05, 2023 09:00 am ET
INVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation Of 23andMe Holding Co (NASDAQ: ME) Data Breach
NEW YORK, Dec. 5, 2023 /PRNewswire/ -- 23andMe, a popular personal genomics and DNA analysis company run by 23andMe Holding Co. ("23 and Me") (NASDAQ: ME), recently suffered a massive data leak. The attack targeted the personal information of 23andMe users -more than 4 million people- compromising individual's personal information such as full name, birth year, email address, and sex, along with information on genetic ancestry, potential relatives, and geolocation. 
Nov 13, 2023 04:30 pm ET
PRIVACY ALERT: Genetic Testing Company 23andMe Faces Class Action Investigation for Cyberattack Potentially Impacting Five Million Customers
23andMe Customers Are Urged to Contact Schubert Jonckheer & Kolbe LLP to Discuss Their Legal Rights
Nov 08, 2023 04:05 pm ET
23andMe Reports Second Quarter Fiscal 2024 Financial Results
23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023. Recent Highlights Consumer...
Nov 07, 2023 08:00 am ET
23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total Health, its new, comprehensive prevention-based health membership that provides clinical grade exome sequencing,...
Nov 06, 2023 08:00 am ET
23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced data from its ongoing first-in-human Phase 1/2a clinical trial evaluating the safety and efficacy of 23ME-00610, an investigational...
Oct 31, 2023 08:00 am ET
23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched Health Action Plan, a new digital tool for 23andMe+ members that draws on results from genetic reports, health history survey data,...
Oct 30, 2023 08:00 am ET
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
23andMe Holding Co. (Nasdaq: ME) (“23andMe”) today announced a new, non-exclusive data license with GSK plc (LSE/NYSE: GSK) which extends their collaboration and enables GSK to conduct drug target discovery and other research using the 23andMe...
Oct 25, 2023 04:05 pm ET
23andMe to Report FY2024 Second Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the...
Sep 27, 2023 04:05 pm ET
23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced two poster presentations on 23ME-00610, an investigational antibody targeting CD200R1, at the Society for Immunotherapy of...
Sep 14, 2023 07:00 am ET
23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, and the non-profit Sickle Cell 101, have joined forces to expand awareness of people’s sickle cell carrier status. The collaboration will include...
Aug 31, 2023 05:28 pm ET
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced the Company has received a U.S. Food and Drug Administration (FDA) 510(k) clearance to expand its existing BRCA1/BRCA2 (Selected...
Aug 08, 2023 04:05 pm ET
23andMe Reports FY2024 First Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, reported its financial results for the first quarter (Q1) of fiscal year 2024 (FY2024), which ended June 30, 2023. 23andMe is the only company with...
Jul 31, 2023 08:30 am ET
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating 23andMe Holding Co. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK, July 31, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of 23andMe Holding Co. (NASDAQ: ME).
Jul 25, 2023 04:05 pm ET
23andMe to Report FY2024 First Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the...
Jul 20, 2023 09:23 am ET
23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, released a new Simvastatin Medication Insight report as part of its 23andMe+ membership service that reports on a person's likelihood of...
Jun 21, 2023 07:00 am ET
23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report as part of the 23andMe+ subscription service on the genetics of panic attacks, or episodes of intense anxiety with...
May 25, 2023 04:05 pm ET
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the fourth quarter (Q4)...
May 16, 2023 07:00 am ET
New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture
23andMe Holding Co. (Nasdaq: ME) (23andMe) today announced that a new survey, which found that primary care physicians are more and more comfortable discussing genetic testing with their patients than they were two years ago, and that more than...
May 11, 2023 04:05 pm ET
23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the fiscal year 2023 (FY2023) fourth quarter and full year after the market closes on...
May 09, 2023 07:00 am ET
23andMe Releases New Report Revealing Likelihood of Developing Lupus
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report on lupus, a chronic autoimmune disease that can in some severe cases lead to permanent tissue damage, and may affect the...
May 08, 2023 07:00 am ET
Reza Afkhami Joins 23andMe as Chief Corporate Development Officer
23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its...
Apr 14, 2023 04:05 pm ET
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced results from the Phase 1 portion of its Phase 1/2a study evaluating 23ME-00610, an investigational antibody targeting CD200R1....
Apr 11, 2023 07:00 am ET
Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program
Today, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, Morehouse School of Medicine (MSM), and the Sickle Cell Foundation of Georgia (SCFG) announced the launch of a Sickle Cell Carrier Status...
Mar 29, 2023 07:01 am ET
23andMe Publishes Inaugural Environmental, Social and Governance Report
ESG report outlines strategic framework and current initiatives for ensuring ethical management, promoting a diverse and equitable culture, and implementing sustainable operations
Mar 24, 2023 07:00 am ET
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
In support of Lipoprotein(a) Awareness Day, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced a collaboration with Novartis Pharmaceuticals Corporation (Novartis) to increase...
Mar 14, 2023 04:30 pm ET
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
23andMe Holding Co. (Nasdaq: ME) (23andMe) announced that clinical data from the Phase 1 portion of the Phase 1/2a study of 23ME-00610 has been selected for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting...
Mar 09, 2023 09:00 am ET
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
A large percentage of people and doctors in the US say that using genetic testing could make healthcare more personalized and effective, according to new surveys by 23andMe. The data comes from two national surveys on attitudes from both primary...
Feb 28, 2023 07:00 am ET
23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, with a mission to help people access, understand and benefit from the human genome, dosed the first patient in the Phase 2a portion of its Phase...
Feb 22, 2023 04:05 pm ET
23andMe to Present at Upcoming Investor Conferences
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be participating in...
Feb 08, 2023 04:05 pm ET
23andMe Reports FY2023 Third Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the third quarter (Q3)...
Jan 26, 2023 04:05 pm ET
23andMe to Report FY2023 Third Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the...
Dec 01, 2022 12:00 pm ET
23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported survey results on how US adults are feeling...
Nov 14, 2022 08:00 am ET
23ANDME (ME) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating 23andMe For Potential Securities Violations and Breaches of Fiduciary Duty
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities violations and breach of fiduciary duty claims against 23andMe Holding Co. (“23andMe” or the...
Nov 07, 2022 04:01 pm ET
23andMe Reports FY2023 Second Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the second quarter...
Nov 07, 2022 08:00 am ET
23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, is presenting a trials-in-progress poster detailing tumor...
Oct 27, 2022 06:45 am ET
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported that the U.S. Food and Drug Administration...
Oct 24, 2022 04:05 pm ET
23andMe to Report FY2023 Second Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the...
Oct 12, 2022 04:10 pm ET
23andMe to Present at Upcoming Investor Conferences
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be participating in...
Oct 05, 2022 08:21 am ET
23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today announced that it will present a trials-in-progress...
Sep 19, 2022 06:45 am ET
Daniel Chu Joins 23andMe as Chief Product Officer
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today appointed Daniel Chu as Chief Product Officer. Prior to joining 23andMe, Chu served as Chief Product Officer for Waymo, where he launched the...
Aug 08, 2022 04:05 pm ET
23andMe Reports FY2023 First Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the first quarter (“Q1”) of...
Jul 25, 2022 04:05 pm ET
23andMe to Report FY2023 First Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2023 (FY2023) first quarter after the market closes on Monday, August 8, 2022....
Jul 21, 2022 08:26 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Missfresh Limited - MF
NEW YORK, July 21, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Missfresh Limited ("Missfresh" or the "Company") (NASDAQ: MF). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
May 26, 2022 04:05 pm ET
23andMe Reports FY2022 Fourth Quarter and Full Year Financial Results
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the fourth quarter (“Q4”)...
May 24, 2022 06:30 am ET
Quarterhill Appoints John Karnes as CFO
TORONTO, May 24, 2022 /PRNewswire/ - Quarterhill Inc. ("Quarterhill" or "the Company") (TSX: QTRH) (OTCQX: QTRHF) announces that John Karnes has been appointed Chief Financial Officer ("CFO") of the Company effective June 6, 2022. Mr. Karnes will replace Steve Thompson, Wi-LAN Inc.'s CFO, who is currently interim-CFO of Quarterhill.
May 24, 2022 06:30 am ET
Quarterhill Appoints John Karnes as CFO
TORONTO, May 24, 2022 /CNW/ - Quarterhill Inc. ("Quarterhill" or "the Company") (TSX: QTRH) (OTCQX: QTRHF) announces that John Karnes has been appointed Chief Financial Officer ("CFO") of the Company effective June 6, 2022. Mr. Karnes will replace Steve Thompson, Wi-LAN Inc.'s CFO, who is currently interim-CFO of Quarterhill.
May 12, 2022 04:10 pm ET
23andMe to Report FY2022 Fourth Quarter and Full Year Financial Results
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 (FY2022) fourth quarter and full year after the market closes on...
Mar 15, 2022 06:45 am ET
23andMe to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and therapeutics company with a mission to help people access, understand, and benefit from the human genome, today announced that it will present data related to its wholly...
Feb 25, 2022 08:30 am ET
23andMe to Present at Cowen 42nd Annual Health Care Conference
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be presenting at the Cowen 42nd...
Feb 17, 2022 09:00 am ET
23andMe to Present at Citi’s 2022 Virtual Healthcare Conference
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be presenting at the Citi 2022...
Feb 10, 2022 04:04 pm ET
23andMe Reports FY2022 Third Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the third quarter (“Q3”)...
Jan 27, 2022 04:05 pm ET
23andMe to Report FY2022 Third Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 (FY2022) third quarter after the market closes on Thursday, February 10,...
Jan 18, 2022 06:55 am ET
23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and therapeutics company, today provided an update on its collaboration with GlaxoSmithKline plc (“GSK”). GSK has elected to exercise its option to extend the exclusive...
Jan 10, 2022 08:00 am ET
23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today received FDA clearance for a genetic health risk report on a hereditary prostate cancer marker. This is the Company’s third cancer risk report...
Jan 06, 2022 09:00 am ET
23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating 23ME-00610 for the treatment of advanced solid tumors....
Dec 28, 2021 04:05 pm ET
23andMe Announces the Results of the Completed Redemption of All Outstanding Warrants
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced the results of the completed redemption (the “Redemption”) of all of its outstanding warrants (the “Warrants”) to purchase shares of...
Nov 30, 2021 09:15 am ET
23andMe Announces the Appointment of Joseph R. Arron, M.D., Ph.D. as Chief Scientific Officer
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and therapeutics company, today announced the appointment of Joseph R. Arron, M.D., Ph.D., as the company’s new Chief Scientific Officer. In this role, Dr. Arron will...
Nov 22, 2021 04:15 pm ET
23andMe Announces Redemption of All Outstanding Warrants
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it will redeem all of its outstanding warrants (the “Public Warrants”) to purchase shares of Class A common stock of 23andMe that...
Nov 10, 2021 04:05 pm ET
23andMe Reports FY2022 Second Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today reported its financial results for the second quarter (“Q2”) of its fiscal year 2022 (“FY2022”), which ended September 30, 2021. “With the...
Nov 09, 2021 03:30 pm ET
23andMe to Present at Upcoming Virtual Healthcare Conferences
SUNNYVALE, Calif., Nov. 9, 2021 /PRNewswire/ -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading consumer genetics and research company, announced today that management will be presenting at three upcoming virtual investor conferences:
Nov 09, 2021 08:00 am ET
23andMe Announces Appointment of Dr. Sandra Hernández to Board of Directors
SUNNYVALE, Calif., Nov. 9, 2021 /PRNewswire/ -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading consumer genetics and research company, today announced the appointment of Dr. Sandra Hernández, President & CEO of the California Health Care Foundation ("CHCF"), to its Board of Directors.
Nov 03, 2021 04:30 pm ET
23andMe Provides Updated Timing for FY2022 Second Quarter Financial Results and Announces New Online Q&A Platform for Shareholders
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 second quarter after market closes on Wednesday, November 10, 2021. The...
Nov 01, 2021 04:05 pm ET
23andMe Announces the Closing of its Acquisition of Lemonaid Health
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it has completed its previously-announced acquisition of Lemonaid Health, Inc. (“Lemonaid Health”), an on-demand platform for...
Oct 22, 2021 06:55 am ET
23andMe Agrees to Acquire Lemonaid Health
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced the signing of a definitive merger agreement with Lemonaid Health, Inc., an on-demand platform for accessing medical care and pharmacy...
Oct 20, 2021 06:30 pm ET
23andMe to Report FY2022 Second Quarter Financial Results on November 10, 2021
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 second quarter before the market opens on Wednesday, November 10, 2021....
Sep 01, 2021 04:05 pm ET
23andMe to Present at the Wells Fargo Healthcare Conference
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that management will be participating in the Wells Fargo Virtual Healthcare Conference on Friday, September 10, 2021 at 8:20 a.m....
Aug 13, 2021 07:00 am ET
23andMe Reports FY2022 First Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today reported its financial results for the first quarter of its fiscal year 2022 (Q1 FY2022), which ended June 30, 2021. “We are excited to...
Jul 29, 2021 07:00 am ET
23andMe to Report FY2022 First Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 first quarter before the market opens on Friday, August 13, 2021. The...
Jun 21, 2021 08:00 am ET
Industry Leaders Join 23andMe Board of Directors
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that, following the June 16 closing of the previously announced business combination between 23andMe, Inc. and VG Acquisition Corp....
Jun 16, 2021 05:29 pm ET
23andMe Successfully Closes its Business Combination with VG Acquisition Corp.
23andMe, Inc., a leading consumer genetics and research company, and VG Acquisition Corp. (NYSE: VGAC), a special purpose acquisition company sponsored by Virgin Group, today announced the completion of their previously announced business...
Jun 10, 2021 04:33 pm ET
Virgin Group's VG Acquisition Corp. Shareholders Approve Business Combination with 23andMe, Inc.
NEW YORK, June 10, 2021 /PRNewswire/ -- VG Acquisition Corp. (NYSE: VGAC), a special purpose acquisition company sponsored by Virgin Group ("VGAC" or the "Company") today announced that its shareholders voted to approve the previously announced merger agreement with 23andMe, Inc. ("23andMe") at VGAC's extraordinary general meeting of shareholders (the "Special Meeting") held earlier today.
Feb 04, 2021 06:05 am ET
23andMe to Merge with Virgin Group's VG Acquisition Corp. to Become Publicly-Traded Company Set to Revolutionize Personalized Healthcare and Therapeutic Development through Human Genetics
SUNNYVALE, Calif. and NEW YORK, Feb. 4, 2021 /PRNewswire/ -- 23andMe, Inc., a leading consumer genetics and research company, and VG Acquisition Corp. (NYSE: VGAC), a special purpose acquisition company sponsored by Virgin Group, announced today that they have entered into a definitive merger agreement. Upon completion of the transaction, estimated in the second calendar quarter of 2021, VGAC will change its New York Stock Exchange (NYSE) ticker symbol, and the combined company's securities will trade under the ticker symbol "ME".

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.